Objectives. To investigate the effects of marijuana in the development of incident cardiovascular and cerebrovascular outcomes.
M
arijuana is the most frequently used illicit drug in the United States. Its use is greatest among young adults, with as many as 35 .1% of high school seniors and 34.4% of college students reporting having used marijuana during the preceding year. 1 Despite its popularity, however, few studies have examined the long-term cardiovascular effects of marijuana.
The acute cardiovascular effects of marijuana include a substantial dose-dependent increase in heart rate, a mild increase in blood pressure, and orthostatic hypotension. [2] [3] [4] However, it is unknown whether these immediate effects heighten the risk for chronic cardiovascular conditions because tolerance is known to develop within several days to a few weeks of use. 5 Case reports have suggested possible links between marijuana use and myocardial infarction, 6, 7 stroke, 8, 9 and cardiac arrthythmias. 10, 11 One study, using a case-crossover design in which cases served as their own controls, showed that marijuana use during the hour before symptom onset was associated with a higher risk of triggering myocardial infarction. 12 Evidence suggests that marijuana may have opposing effects on the long-term development of atherosclerosis and cardiovascular disease (CVD). 13 The main components of marijuana are the cannabinoids, the active ingredients of marijuana. Cannabinoid receptors CB1 and CB2 are widely distributed in the cardiovascular system. 14 In mice, activating the CB2 receptor has been shown to suppress the inflammatory response 15 ; therefore, this might protect marijuana smokers from developing atherosclerosis. Activating the CB1 receptor, conversely, might increase atherosclerosis, because inhibiting CB1 may protect against atherosclerosis. 16 Despite these potential mechanisms, weak and inconsistent associations have been observed between cumulative marijuana use and subclinical atherosclerosis. 17 Contrary to the previously cited retrospective studies and case reports that claim that marijuana may be an acute trigger of myocardial infarction and other cardiovascular outcomes, longitudinal prospective studies have failed to detect adverse effects of marijuana use on cardiovascular risk factors, 18, 19 hospitalizations for cardiovascular conditions, 20 or mortality. 21, 22 However, these few available prospective studies have generally been limited by only a single assessment and crude classification of marijuana use (e.g., current or former user) or the absence of carefully conducted clinical cardiovascular or cerebrovascular event collection, adjudication, and classification. We investigated the recent and long-term effects of marijuana use in the development of multiple incident cardiovascular and cerebrovascular outcomes in middle age among a population-based sample of participants with marijuana use typical of the communities in which they live. We estimated both the recent frequency and cumulative lifetime exposure to marijuana using repeated measurements beginning in young adulthood. To date, participants have been reexamined 2, 5, 7, 10, 15, 20, and 25 years after baseline. Participation rates across these examinations were 91%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively, of the surviving cohort. Additionally, 94% of the surviving cohort were contacted by telephone or examination from 2009 to 2014.
METHODS

Measurements
Standardized protocols for data collection were used across study centers and examinations. Participants were asked to fast for at least 12 hours before each examination and to avoid smoking or engaging in heavy physical activity for at least 2 hours.
Recent marijuana use was assessed at each in-person CARDIA examination (at baseline and after 2, 5, 7, 10, 15, 20, and 25 years of follow-up) using the following survey question: "During the last 30 days, on how many days did you use marijuana?" Direct selfreported lifetime exposure was also assessed at each examination using the question "About how many times in your lifetime have you used marijuana?" We used recent and lifetime use to compute marijuana-years, with 1 year of exposure equivalent to daily marijuana use. 23 We assumed that recent use at each examination (i.e., the number of days of using marijuana during the month before each examination) reflected the average number of days of use during the months before each examination.
We estimated cumulative lifetime use by adding the total number of days using marijuana during follow-up up until the examination immediately preceding the date of the clinical cardiovascular event, date of death, or last date of contact. We adjusted our estimate upward whenever self-reported lifetime marijuana use reported at baseline and each follow-up examination was higher than our computed estimate. 23 We defined recent marijuana use as recent use as of the examination immediately before the date of the clinical cardiovascular event, date of death, or last date of contact. We classified cumulative lifetime and recent marijuana use into previously defined categories, including never, 1 day to less than 0.5 marijuana-years, 0.5 to less than 2.0 marijuana-years, 2.0 to less than 5.0 marijuana-years, and 5.0 or more marijuana-years, and none, 1 to 9 days, 10 to 19 days, and 20 or more days, respectively. 24 We recorded new cardiovascular and cerebrovascular events from the baseline examination through August 2013. During scheduled study examinations and yearly telephone interviews, each participant or designated proxy was asked about interim hospital admissions, outpatient procedures, and deaths. Designated proxies did not participate in the examination. We requested medical records for participants who had been hospitalized or received an outpatient revascularization procedure. Vital status was assessed every 6 months; we requested medical and other death records after consent had been obtained from the next of kin.
Two physician members of the Endpoints Committee blinded to participant marijuana use independently reviewed medical records and recorded information to adjudicate each possible cardiovascular or cerebrovascular event or underlying cause of death using specific definitions and a detailed manual of operations (http://www.cardia.dopm.uab. edu). If disagreement occurred between the primary reviewers, the full committee reviewed the case. The primary composite outcome was incident CVD, which included coronary heart disease ([CHD] myocardial infarction, acute coronary syndrome, or CHD death, including fatal myocardial infarction), stroke, transient ischemic attack (TIA), hospitalization for heart failure, intervention for peripheral arterial disease, or death from cardiovascular causes. Secondary cause-specific outcomes included stroke or TIA, CHD, and CVD mortality.
We measured education as the maximum educational grade attained. We measured physical activity with the CARDIA Physical Activity History questionnaire, which asks about the amount of time per week spent in 13 categories of leisure, occupational, and household physical activities over the past 12 months. Body mass index was calculated at each examination as weight in kilograms (measured to the nearest 0.5 kg using a balance beam scale) divided by height in meters (measured with a vertical ruler to the nearest 0.5 cm) squared. We used cigarette smoking behavior, collected at each examination, to estimate cumulative lifetime exposure to cigarettes in terms of pack-years, with 1 pack-year of exposure equivalent to smoking 1 pack of cigarettes per day for a year. 23 We estimated cumulative lifetime alcohol consumption in drink-years, defining 1 drink-year as the amount of alcohol consumed in 1 year by a person consuming 1 drink per day. 25 We defined acute heavy exposure to alcohol (bingeing) as reporting 5 or more drinks on 1 occasion, and we estimated total cumulative lifetime episodes. We estimated total number of cumulative lifetime exposures to cocaine (including other forms of cocaine, e.g., crack, powder, and free base), amphetamines (speed, uppers, methamphetamines), and opioids for nonmedical reasons (including heroin) based on repeat assessments. 26 History of myocardial infarction or stroke in a first degree male or female relative was queried at baseline and years 5, 10, and 25.
We defined hypertension at each examination as a systolic blood pressure of ‡ 140 millimeter of mercury, of diastolic blood pressure 90 millimeter of mercury or greater, or antihypertensive medication use. 27 We determined diabetes from a combination of measured fasting glucose levels ( ‡ 7.0 mmol/L; ‡ 126 mg/dL) at baseline and years 7, 10, 15, 20, and 25; self-report of oral hypoglycemic medications or insulin (all examinations); a 2-hour postload glucose of 11.1 millimole per liter or greater ( ‡ 200 mg/dl) at years 10, 20, and 25; or a glycated hemoglobin A 1c of 6.5% or greater at years 20 and 25.
28 Self-reported depression was measured every 5 years starting at year 5 using the Center for Epidemiologic Studies Depression scale. We defined depression as a Center for Epidemiologic Studies Depression scale score of 16 or greater. Dyslipidemia at each examination was defined as a low high-density lipoproteins cholesterol (< 40 mg/dL for men; < 50 mg/dL for women), high low-density lipoproteins cholesterol ( ‡ 160 mg/dL), high triglycerides ( ‡ 200 mg/dL), or lipid-lowering medication use. 29 
Statistical Analysis
We described participant characteristics overall and by cumulative lifetime use of marijuana using means, medians, and proportions as appropriate. We conducted descriptive analyses using linear regression models and c 2 analyses for continuous and categorical variables, respectively. We calculated incidence rates per 1000 person-years overall and according to marijuana use. We calculated follow-up time as the difference between the baseline examination date and the event date, date of death, or the date of last contact (whichever came first).
We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for our primary (total CVD) and secondary (stroke or TIA, CHD, and CVD mortality) outcomes. We included marijuana use as a time-dependent variable in 1 of 2 exposure forms: cumulative lifetime use or recent use. We adjusted our model for sociodemographic characteristics (i.e., age, gender, race, educational attainment), study center, and factors potentially associated with marijuana use and CVD selected a priori, including family history of cardiovascular disease and time-varying physical activity (average self-reported exercise units), body mass index (average kg/m 2 ), high blood pressure, diabetes, dyslipidemia, depression, smoking (pack-years), cumulative alcohol use (drinkyears), cumulative binge drinking episodes, and cumulative use of other illicit drugs (cocaine, crack, speed, methamphetamine, or opioids).
We performed tests for a linear trend by entering the categorical marijuana use variable into the models as a continuous term. We assessed potential effect modification by age, gender, race, and family history of CVD by testing multiplicative interaction. To evaluate the potential for informative censoring, we estimated sub-HRs and 95% CIs for our primary and secondary outcomes in a FineGray competing risk model, in which the competing event was mortality from causes other than CVD. 30 Power calculations demonstrated greater than 80% power to detect extreme category HRs (i.e., for the comparison of never any marijuana use with ‡ 5 marijuana-years) greater than 1.61. We used multiple imputation (5 times) to impute missing examination values using the sequential regression imputation approach that is implemented in the software package IVEware version 0.2 (Institute for Social Research, University of Michigan, Ann Arbor, MI). 31 We analyzed each data set separately and combined results from the 5 analyses using the rules of Little and Rubin. 32 Tests of statistical significance were 2-tailed, with an a level of 0.05. We used SAS version 9.4 (SAS Institute, Cary, NC) to perform all statistical analyses.
RESULTS
Of the 5115 participants, we excluded 1 who reported having had a myocardial infarction at the baseline examination and another who withdrew consent for study participation. Of the remaining 5113 participants, most (n = 4286; 84%) reported having used marijuana before or during follow-up, but most had relatively few cumulative lifetime years of exposure. Median cumulative lifetime marijuana use was 0.51 (interquartile range = 0.02-2.40) marijuanayears. Cumulative lifetime marijuana use was associated with male gender, Black race, less educational attainment, greater physical activity, other substance use, and a positive family history of CVD (Table A, available as a supplement to the online version of this article at http://www.ajph.org). Marijuana use was not associated with other risk factors for CVD, including age, body mass index, depression, hypertension, diabetes, or dyslipidemia (Table A) .
During a median 26.9 years of follow-up (interquartile range = 26.7, 27.0; 131 990 person-years), we identified 215 total CVD events (1.63 per 1000 person-years), including 62 strokes or TIAs (0.47 per 1000 person-years), 104 cases of CHD (0.78 per 1000 person-years), and 50 CVD deaths (0.38 per 1000 person-years). Table 1 shows the number of incident events; incidence rates; and adjusted HRs for total CVD, stroke or TIA, CHD, and CVD mortality according to cumulative lifetime marijuana use. In multivariable-adjusted analyses, cumulative lifetime marijuana use was not associated with incident CVD. Likewise, cumulative lifetime marijuana use showed no associations with stroke or TIA, CHD, or CVD mortality in adjusted analyses. Table 2 displays the number of incident events; incidence rates; and adjusted HRs for total CVD, stroke or TIA, CHD, and CVD mortality according to recent marijuana use, which was reported by 18.8% (n = 960) of the cohort. Compared with no recent use, categories of recent marijuana use showed no evidence for a higher or lower risk for incident CVD, stroke or TIA, CHD, or CVD mortality in adjusted analyses. Tables B and C (available as supplements to the online version of this article at http://www.ajph. org) display the adjusted HRs for total CVD according to cumulative lifetime and recent marijuana use, respectively, within strata of participants defined by age, gender, race, and family history of CVD. We found no consistent evidence that cumulative lifetime (Table B) or recent (Table C) marijuana use was associated with incident CVD events within these strata of participants.
Tables D and E (available as supplements to the online version of this article at http:// www.ajph.org) display the adjusted HRs for total CVD, stroke or TIA, CHD, and CVD mortality according to cumulative lifetime and recent marijuana use, respectively, from a Fine-Gray competing risk model in which the competing event was mortality from causes other than CVD. The sub-HRs for total CVD, stroke or TIA, CHD, and CVD mortality according to cumulative lifetime (Table D) and recent (Table E) marijuana use were similar to the HRs without considering competing risk from other causes of death (Tables 1 and 2 , respectively).
DISCUSSION
In this community-based cohort of young adults followed for more than 25 years, we found no evidence to suggest that cumulative lifetime or recent marijuana use, at levels typical of most recreational, occasional users of marijuana in the United States, affects risk of future CVD events through middle age. Furthermore, we found no significant associations between CVD risk and cumulative lifetime or recent marijuana use in subgroups defined by age, gender, race, or family history of CVD (Tables B and C ). In addition, there was no suggestion that these null results were attributable to competing risks of death from other causes (Tables D and E) .
We believe this is the first long-term study of cumulative lifetime marijuana use and incidence of fatal and nonfatal CVD events later in life. Our results are consistent with a recent case-control study of ischemic stroke or TIA patients that observed no evidence for an association with marijuana use. 33 Similarly, in a cohort study conducted in a large health maintenance organization, Sidney et al. 20 found no evidence that currently or ever using marijuana influenced the risk of death from CVD or hospitalization for myocardial infarction, CHD, stroke, or CVD during follow-up. Likewise, among a cohort of myocardial infarction survivors, marijuana use in the year before symptom onset was not associated with long-term CVD mortality. 21, 34 Our findings are also consistent with a limited number of studies of marijuana use, subclinical atherosclerosis, 17 and risk factors for CVD, 18, 19 including an earlier report from CARDIA that showed no evidence for an association of cumulative marijuana use over a 15-year period with systolic blood pressure, fasting glucose levels, lipids, or adiposity. 18 By contrast, many case reports have implicated marijuana in the occurrence of clinical CVD events. [6] [7] [8] [9] [10] [11] However, whereas case reports are useful in suggesting possible links between an exposure, such as marijuana use, and outcomes, they do not establish an etiologic role, because of the absence of a comparison group. Nevertheless, there is evidence that marijuana may be a rare trigger of acute ischemic CHD. In a case-crossover design among 3882 patients hospitalized after acute myocardial infarction, Mittleman et al. 12 showed that marijuana use during the hour before symptom onset increased risk of myocardial infarction by 4.8 times over the baseline risk (95% CI = 2.4, 9.5) and decreased it rapidly thereafter. This finding was derived from only 9 (0.2%) exposed cases. Additional evidence that marijuana may be a rare trigger of ischemic CHD has come from double-blind experimental studies conducted among patients with chronic stable angina. In these studies, Aronow and Cassidy 35, 36 determined that exercise time until the onset of angina decreased significantly more by smoking 1 marijuana cigarette than by smoking a placebo marijuana cigarette or a high-nicotine cigarette. Although we were unable to test the hypothesis that marijuana may acutely increase the risk of CHD, we found no indication for an association according to recent use.
One potential explanation for our observed lack of an association between marijuana use and CVD events in later life is the relatively low lifetime dose compared with other CVD risk factors. Although most participants reported a history of marijuana use, total marijuana-years were low, consistent with the observation that a typical marijuana user smokes less than 1 marijuana cigarette per day and generally quits using marijuana early in adulthood. 37 Another potential reason for the lack of an association of marijuana use and CVD events is the opposing cardiovascular effects of cannabinoids, via cannabinoid receptors CB1 and CB2. 13, 14 Activation of CB1 receptors has been shown in mouse models to promote a proathergenic profile, 16 whereas activation of CB2 receptors may suppress the inflammatory response, 15 thereby reducing the progression of atherosclerosis.
Strengths and Limitations
Study strengths include a communitybased sampling method as opposed to a clinic-based sample; repeated assessments of and extensive data on marijuana use and potential confounding factors beginning early in adulthood; adjudication of suspected cardiovascular outcomes by a panel of physicians using detailed evaluation criteria; a biracial cohort; a relatively large sample size well balanced with respect to age, gender, race, and education that increased precision and permitted simultaneous adjustment and stratification by multiple variables; high retention; and the standardized data collection protocols and rigorous quality control of the CARDIA study.
At least 3 limitations deserve mention. First, our measures of marijuana use lacked information on the exact dosage and were derived from self-report, which may not always be reliable, especially for an illicit substance. This may have contributed to our null findings. However, repeat assessments of marijuana use were incorporated into our measure of cumulative lifetime exposure, our questionnaire was self-administered rather than interviewer administered, the survey was completed in a research clinic as opposed to a government agency or employer facility, and confidentiality was ensured at each examination.
Second, we relied, at least initially, on participant self-report of cardiovascularrelated hospitalizations or procedures performed in an outpatient setting before medical record adjudication, which may not be reliable among long-term or heavy marijuana users. 38 However, we confirmed null associations in analyses of marijuana use and CVD mortality, an outcome independent of participant self-report. Third, the relatively small number of outcomes and somewhat few recent marijuana users limited the precision of our estimates, particularly in analyses of our secondary cause-specific outcomes. Thus, our results should be confirmed in studies of large cohorts with high cumulative marijuana use.
Conclusions
With the increasing use of marijuana and decreasing perceived harmfulness, evaluation Note. AHR = adjusted hazard ratio; CARDIA = the Coronary Artery Risk Development in Young Adults study; CI = confidence interval. The sample size was n = 5113. We assessed the number of participants who used marijuana over the last 30 d during the examination immediately before the date of the clinical cardiovascular event, date of death, or the last date of contact.
a Per 1000 person-years. b Adjusted for age, gender, race, educational attainment, and study center as well as family history of cardiovascular disease and time-varying physical activity, body mass index, high blood pressure, diabetes, dyslipidemia, depression, smoking (pack-years), cumulative alcohol use, cumulative binge drinking episodes, and cumulative use of other illicit drugs (cocaine, crack, speed, methamphetamine, or opioids).
